Hypofractionated Radiotherapy With a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer
Eligible age
18+ yrs
Accepts
Men
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study is for adult men with previously untreated high risk, very high risk, or pelvic lymph node positive prostate cancer. The purpose of this study is to evaluate the safety and effectiveness of the combination of two emerging radiation treatment techniques (hypofractionated radiotherapy and microboost technique). Participation will include standard of care visits along with questionnaires and blood draws completed for research purposes. There is optional banking of blood and prostate biopsy tissue which will not require extra biopsies. Participation in this study is anticipated to last approximately 6 weeks with follow up every three months for two years then twice yearly for years 3-5.
Sponsor: Medical University of South Carolina
You may qualify if…
- ✓ 1. Provision of signed and dated informed consent form.
- ✓ 2. Stated willingness to comply with all study procedures and availability for the duration of the study.
- ✓ 3. Biologically male patients aged 18 years and older.
- ✓ 4. Ability to receive pelvic radiotherapy and be willing to adhere to the protocol regimen.
- ✓ 5. Previously untreated prostate cancer (with cytotoxic chemotherapy, cryotherapy, ablative treatment, surgical or radiation therapy). Prior transurethral resection of prostate (TURP) is permitted if 90 days or more prior to the start of radiotherapy.
- ✓ 6. Localized or locally advanced prostate cancer meeting NCCN criteria for high risk, very high risk or non-metastatic, pelvic lymph node positive defined as having at least one or more of the following:
- ✓ 1. PSA \>20 ng/mL prior to starting ADT.
- ✓ 2. cT3a-T4 by digital exam or imaging.
You may not qualify if…
- ✕ 1\. Concurrent use of testosterone supplementation unless discontinued by time of registration.
- ✕ 2\. Definitive radiologic evidence of metastatic disease outside of the pelvic nodes on conventional imaging (bone scan, CT scan, MRI).
- ✕ 3\. Prior pelvic radiotherapy. 4. Pre-existing conditions or overall health status which disqualifies the patient from curative intent-RT. Patients with life expectancy less than 5 years are not eligible.
- ✕ 5\. Treatment with another investigational prostate cancer therapy within 12 months.
- ✕ 6\. Prior total prostatectomy, cryotherapy, high-intensity focused ultrasound, irreversible electroporation, MRI ablation, laser ablation, transurethral ultrasound ablation, aquablation directed towards the prostate for any prostate disease or condition.
- ✕ 7\. Prior or concurrent invasive pelvic malignancy (except non-melanomatous skin cancer) or lymphomatous or hematogenous malignancy, unless disease free for a minimum of 5 years.
- ✕ 8\. Any condition that, in the opinion of the investigator, would preclude participation in this study.
- ✕ 9\. Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset of androgen ablation (both LHRH agonist and oral anti-androgen) is ≤ 90 days prior to registration.
Where it's recruiting
Charleston
Source: ClinicalTrials.gov · NCT07325721 · last updated 2026-02-05